Compare CPIX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPIX | SLGL |
|---|---|---|
| Founded | 1999 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.1M | 117.8M |
| IPO Year | 2009 | 2018 |
| Metric | CPIX | SLGL |
|---|---|---|
| Price | $4.12 | $41.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | ★ 224.3K | 16.0K |
| Earning Date | 11-04-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $41,278,349.00 | $18,970,000.00 |
| Revenue This Year | N/A | $121.82 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 12.21 | ★ 62.04 |
| 52 Week Low | $1.85 | $4.02 |
| 52 Week High | $7.25 | $52.26 |
| Indicator | CPIX | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 73.82 | 53.60 |
| Support Level | $3.93 | $38.91 |
| Resistance Level | $4.59 | $43.12 |
| Average True Range (ATR) | 0.42 | 3.32 |
| MACD | 0.16 | -0.09 |
| Stochastic Oscillator | 80.28 | 51.15 |
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.